Gain TherapeuticsGANX
GANX
About: Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
Employees: 25
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
500% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 2
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
176% more call options, than puts
Call options by funds: $47K | Put options by funds: $17K
32% more funds holding
Funds holding: 25 [Q4 2024] → 33 (+8) [Q1 2025]
7% more capital invested
Capital invested by funds: $7.68M [Q4 2024] → $8.24M (+$560K) [Q1 2025]
2.64% more ownership
Funds ownership: 7.48% [Q4 2024] → 10.11% (+2.64%) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
247%
upside
Avg. target
$7
305%
upside
High target
$8
362%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju | 362%upside $8 | Buy Reiterated | 19 May 2025 |
Chardan Capital Keay Nakae | 247%upside $6 | Buy Maintained | 28 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
6 days ago
Gain Therapeutics to Participate in Upcoming Investor Conferences
BETHESDA, Md., June 10, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present at two upcoming investor conferences: H.C.
Neutral
GlobeNewsWire
2 weeks ago
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
BETHESDA, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral presentation at the GBA1 Meeting 2025, being held June 5th-7th in Montreal, Canada.
Neutral
GlobeNewsWire
1 month ago
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected Mid-2025 First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected Mid-2025
Neutral
GlobeNewsWire
1 month ago
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders
GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activity GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activity
Neutral
GlobeNewsWire
1 month ago
Gain Therapeutics to Participate at The Citizens Life Sciences Conference
BETHESDA, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present and participate in one-on-one meetings at The Citizens Life Sciences Conference, being held May 7th-8th in New York City, NY.
Neutral
GlobeNewsWire
1 month ago
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders
BETHESDA, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral poster presentation at the International Association of Parkinsonism and Related Disorders (IAPRD) 30th World Congress on Parkinson's Disease and Related Disorders, being held May 7th-10th in New York City, NY.
Neutral
GlobeNewsWire
2 months ago
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
BETHESDA, Md., March 28, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a poster detailing the design of the Phase 1b clinical trial of GT-02287 in Parkinson's disease will be presented at the AD/PD™ 2025 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders. AD/PD™ 2025 is being held April 1-5, 2025, in Vienna, Austria.
Neutral
GlobeNewsWire
2 months ago
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
First Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected in Q2 2025 First Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected in Q2 2025
Neutral
GlobeNewsWire
3 months ago
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease
BETHESDA, Md., March 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the dosing of the first participant with Parkinson's disease (PD) in its Phase 1b clinical trial of GT-02287, the Company's lead allosteric small molecule in development for the treatment of PD with or without a GBA1 mutation.
Neutral
GlobeNewsWire
3 months ago
Gain Therapeutics Announces Oral Presentation at AD/PD 2025
BETHESDA, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Joanne Taylor, Ph.D., Senior Vice President of Research at Gain, will give an oral presentation on the Company's clinical stage lead drug candidate GT-02287 at the AD/PD™ 2025 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders. AD/PD™ 2025 is being held April 1-5, 2025, in Vienna, Austria.
Charts implemented using Lightweight Charts™